Modified Quantitative and Volumetric Response Evaluation Criteria for Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 10

PMID 36761945

Authors

Jiachen Xu

Yu Yin

Jun Yang

Li Chen

Zhi Li

Jian Shen

Wansheng Wang

Caifang Ni

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to investigate the cutoff value of quantitative and volumetric response evaluation criteria for patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) and compare the performance of the modified criteria to one-dimensional criteria in survival prediction.

Methods: A retrospective single-center study was performed for treatment-naive patients with HCC who underwent initial TACE between June 2015 and June 2019. Treatment response assessment was performed after the first observation by contrast CT or MRI, with the measurement of diameters by modified Response Evaluation Criteria in Solid Tumors (mRECIST) and volumes by quantitative European Association for Study of the Liver (qEASL). Overall survival (OS) was the primary endpoint of this study. The new cutoff value for volumetric response evaluation criteria was created using restricted cubic splines. The performance of modified qEASL (mqEASL, with the new cutoff value) and mRECIST on survival prediction was compared by Cox regression models in internal and external validation.

Results: A total of 129 patients (mean age, 60 years ± 11 [standard deviation]; 111 men) were included and divided into training (n=90) and validation (n=39) cohorts. The cutoff value for the viable volume reduction was set at 57.0%. The mqEASL enabled separation of non-responders and responders in terms of median OS (p<0.001), 11.2 months (95% CI, 8.5-17.2 months) vs. 31.5 months (95% CI, 25.5-44.0 months). Two multivariate models were developed with independent prognostic factors (tumor response, metastasis, portal vein tumor thrombus, and subsequent treatment) to predict OS. Model 2 (for mqEASL) had a greater Harrel's C index, higher time-dependent area under the receiving operator characteristic curve (AUROC), and more precise calibration on 6-month survival rates than Model 1 (for mRECIST).

Conclusions: With the modified cutoff value, the quantitative and volumetric response of HCC patients to TACE becomes a precise predictor of overall survival. Further studies are needed to verify this modification before application in clinical practice.

Citing Articles

Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.

Zhao B, Obuchowski N, Yang H, Chou Y, Ma H, Guo P Radiol Adv. 2025; 2(1):umaf001.

PMID: 39834611 PMC: 11739520. DOI: 10.1093/radadv/umaf001.

References

Georgiades C, Geschwind J, Harrison N, Hines-Peralta A, Liapi E, Hong K . Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?. Radiology. 2012; 265(1):115-23. PMC: 4137783. DOI: 10.1148/radiol.12112264. View

Choi J, Shim J, Shin Y, Kim K, Lim Y, Lee H . Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol. 2014; 60(6):1212-8. DOI: 10.1016/j.jhep.2014.01.014. View

King M, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K . Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. Eur J Radiol. 2020; 133:109351. DOI: 10.1016/j.ejrad.2020.109351. View

Adhoute X, Penaranda G, Naude S, Raoul J, Perrier H, Bayle O . Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2014; 62(4):855-62. DOI: 10.1016/j.jhep.2014.11.014. View

Llovet J, Lencioni R . mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020; 72(2):288-306. DOI: 10.1016/j.jhep.2019.09.026. View

Llovet J, Montal R, Villanueva A . Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol. 2019; 70(6):1262-1277. DOI: 10.1016/j.jhep.2019.01.028. View

Bonekamp S, Li Z, Geschwind J, Halappa V, Corona-Villalobos C, Reyes D . Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology. 2013; 268(2):420-30. PMC: 3721055. DOI: 10.1148/radiol.13122307. View

Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K . Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020; 26(2):155-162. PMC: 7160341. DOI: 10.3350/cmh.2019.0021n. View

Park C, Chu H, Kim J, Kim S, Alrashidi I, Gwon D . Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. J Vasc Interv Radiol. 2020; 31(12):1998-2006.e1. DOI: 10.1016/j.jvir.2020.04.017. View

10.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

11.

Lin M, Pellerin O, Bhagat N, Rao P, Loffroy R, Ardon R . Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial.... J Vasc Interv Radiol. 2012; 23(12):1629-37. PMC: 3579576. DOI: 10.1016/j.jvir.2012.08.028. View

12.

Lencioni R . New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res. 2013; 19(6):1312-4. DOI: 10.1158/1078-0432.CCR-12-3796. View

13.

Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S . Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?. Cardiovasc Intervent Radiol. 2017; 41(3):433-442. PMC: 5803331. DOI: 10.1007/s00270-017-1829-4. View

14.

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin J, Pujol S . 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012; 30(9):1323-41. PMC: 3466397. DOI: 10.1016/j.mri.2012.05.001. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Chapiro J, Wood L, Lin M, Duran R, Cornish T, Lesage D . Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014; 273(3):746-58. PMC: 4263418. DOI: 10.1148/radiol.14140033. View

17.

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

18.

Forner A, Reig M, Rodriguez de Lope C, Bruix J . Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1):61-74. DOI: 10.1055/s-0030-1247133. View

19.

Mak L, Cruz-Ramon V, Chinchilla-Lopez P, Torres H, Loconte N, Rice J . Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2018; 38:262-279. DOI: 10.1200/EDBK_200939. View

20.

Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J . Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2015; 278(1):275-84. PMC: 4695977. DOI: 10.1148/radiol.2015142951. View